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Abstract 
 
Inflammation is associated with production of reactive oxygen species (ROS) and 
results in the induction of thioredoxin (TXN) and peroxiredoxins (PRDXs) and 
activation of nuclear factor-like 2 (Nrf2). In this study we have used the mouse RAW 
264.7 macrophage and the human THP-1 monocyte cell line to investigate the 
pattern of expression of three Nrf2 target genes, PRDX1, TXN reductase (TXNRD1) 
and heme oxygenase (HMOX1), by activation of different Toll-like receptors (TLR). 
We found that, while the TLR4 agonist lipopolysaccharide (LPS) induces all three 
genes, the pattern of induction with agonists for TLR1/2, TLR3, TLR2/6 and TLR7/8 
differs depending on the gene and the cell line. In all cases, the extent of induction 
was HMOX1>TXNRD1>PRDX1. Since LPS was a good inducer of all genes in both 
cell lines, we studied the mechanisms mediating LPS induction of the three genes 
using mouse RAW 264.7 cells. To assess the role of ROS we used the antioxidant 
N-acetylcysteine (NAC). Only LPS induction of HMOX1 was inhibited by NAC while 
that of TXNRD1 and PRDX1 was unaffected. These three genes were also induced 
by phorbol myristate acetate (PMA), a ROS-inducer acting by activation of protein 
kinase C (PKC).  The protein kinase inhibitor staurosporine inhibited the induction of 
all three genes by PMA but only that of HMOX1 by LPS. This indicates that 
activation of these genes by inflammatory agents is regulated by different 
mechanisms involving either ROS or protein kinases, or both.  
 
 
Keywords: Nrf2, Toll-like receptors, antioxidant, inflammation, peroxiredoxin, 
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Introduction 
Toll-like receptors (TLRs) respond to various pathogen-associated molecular patterns 
[1, 2] as well as damage-associated molecular patterns released in response to 
damage or stress [3], leading to the production of proinflammatory cytokines [1, 2]. 
TLR stimulation increases generation of reactive oxygen species (ROS) which have 
multiple roles in inflammation, including pathogen defence, redox signalling [4] and 
activation of redox-sensitive transcription factors including NF-κB and nuclear factor-
like 2 (Nrf2; encoded by the gene nuclear factor erythroid-derived 2-Like 2, NFE2L2) 
[5, 6]. Inflammatory stimuli activate the expression of protein thiol-disulfide 
oxidoreductases (PDORs) Nrf2 target genes, including thioredoxin (TXN) and 
peroxiredoxins (PRDXs), along with heme oxygenase (HMOX1) [6].  
In addition to their well known antioxidant action [7], PDORs can regulate 
inflammation. PRDX overexpression inhibits production of inflammatory cytokines in 
RAW 264.7 mouse macrophages [8], while extracellular PRDX induces the 
production of inflammatory cytokines [9, 10].  Likewise, TXN overexpression can 
dampen inflammation [11], but extracellular TXN can act as a chemokine [12]  and 
participate in neutrophil migration. 
This aim of this study was to investigate whether activation of different TLRs results 
in a different pattern of induction of PRDX1, TXNRD1, and HMOX1, using mouse 
RAW 264.7 macrophage and human THP-1 monocyte cell lines. We also studied the 
role of protein kinase C (PKC) and ROS in their induction using phorbol myristate 
acetate (PMA) that stimulates production of reactive oxygen species (ROS) via 
protein kinase C (PKC) [13], or the thiol antioxidant N-acetylcysteine (NAC).  
 
Methods 
All chemicals and solutions were purchased from Sigma-Aldrich Corporation (St. 
Louis, USA) unless otherwise stated.  
2.1 Cell culture 
RAW 264.7 and THP-1 cells were maintained at 37°C and 5% CO2 in RPMI 
containing 2mM L-glutamine, supplemented with 50 U/ml penicillin, 50 µg/ml 
streptomycin (Thermo Fisher Scientific, Waltham, USA) and 10% heat inactivated 
5 
 
foetal calf serum. For experiments RAW cells were seeded at 1.25x105/ml and THP-
1 cells at 5x105/ml in 24- or 96-well plates. RAW cells were incubated overnight to 
allow adhesion prior to TLR stimulation; THP-1 cells were stimulated one hour after 
seeding. 
TLR stimulation was carried out for 6h (RT-qPCR) or 24h (tumour necrosis factor 
(TNF) production) using the following TLR agonists: the synthetic tripalmitoylated 
lipohexapeptide analogue of the immunologically active N-terminal portion of 
bacterial lipoprotein Pam3 (TLR1/2; 1 µg/ml in RAW and 100 ng/ml in THP-1; 
InvivoGen, Toulouse, France), polyinosinic-polycytidylic acid (poly IC) (TLR3; 12.5 
µg/ml; InvivoGen), LPS (TLR4; 10 ng/ml in RAW and 100 ng/ml in THP-1; 055:B5), 
neoseptin (TLR4; 25 µM), FSL-1 (TLR2/6; 200 ng/ml in RAW and 20 ng/ml in THP-1; 
InvivoGen), R-848 (TLR7/8; 1 µg/ml in RAW and 10 µg/ml in THP-1; InvivoGen), 
CL075 (TLR7/8; 10 µg/ml; InvivoGen), ODN 2216 (TLR9; 5 µM; InvivoGen). PMA 
was used at 500 ng/ml. NAC (10 mM) or staurosporine (100 nM) were applied to 
cells prior to TLR stimulation for 1h and 30mins respectively. TNF production was 
quantified using a DuoSet ELISA kit (Bio-Techne, Minneapolis, Minnesota, USA).  
2.2 TaqMan RT-qPCR 
Total RNA was extracted from cells using QIAzol (QIAGEN, Hilden, Germany), 
following manufacturer instructions. Reverse transcription (RT) and TaqMan qPCR 
analysis of PRDX1 (mouse, Mm01621996_s1; human, Hs00602020_mH), TXNRD1 
(mouse, Mm00443675_m1; human, Hs00917067_m1) and HMOX1 (mouse, 
Mm00516005_m1; human, Hs01110250_m1) gene expression was performed as 
previously reported [14]. Gene expression was quantified using the comparative 
threshold cycle method, according to Applied Biosystems’ guideline. Results were 
normalised to HPRT1 (mouse, Mm00446968_m1; human, Hs99999909_m1) and 
expressed as fold change of one of the control samples, chosen as the calibrator. All 
TaqMan gene expression assays were purchased from Life Technologies (Carlsbad, 
USA). 
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Results 
3.1 Differential induction of PRDX1, TXNRD1 and HMOX1 by TLR agonists 
Expression of PRDX1, TXNRD1 and HMOX1 expression was investigated in mouse 
RAW 264.7 cells following 6h stimulation with each TLR agonist. The doses were 
selected based on previous studies [14-21]. We confirmed that at these doses all TLR 
ligands induced significant amounts of TNF in RAW 264.7 cells after 24h stimulation 
(data not shown), as previously reported in other cell types [19, 22-24].  
LPS increased PRDX1 expression 2.5-fold, while other TLR agonists had no effect 
(Figure 1A). In contrast, TXNRD1 expression was increased in response to LPS 
(TLR4), CL075 (TLR7/8) and R-848 (TLR7/8), and HMOX1 expression was increased 
by LPS (TLR4), Pam3 (TLR1/2), poly IC (TLR3), CL075 (TLR7/8) and R-848 (TLR7/8), 
indicating that each of these genes is regulated differently (Figures 1B and 1C).  
The pattern of induction of PRDX1, TXNRD1 and HMOX1 in human THP-1 cells was 
different, as shown in Figure 2. RAW 264.7 cells are more sensitive to stimulation 
with LPS than THP-1 cells; therefore, the concentration of LPS was increased 10-
fold, from 10 ng/ml in RAW cells to 100 ng/ml in THP-1, in order to achieve 
significant levels of TNF production (about 700 pg/ml, not shown). On the other 
hand, the concentrations of Pam3 (TLR1/2) and FSL-1 (TLR2/6) were decreased 10-
fold, from 1 µg/ml and 200 ng/ml in RAW cells to 100 ng/ml and 20 ng/ml in THP-1 
cells respectively, to elicit production of TNF levels comparable to LPS (not shown). 
Unlike RAW 264.7 cells, where only LPS induced PRDX1, induction of PRDX1 was 
observed also with Pam3 and FSL-1. Induction of PRDX1 was at most about 2-fold 
whereas induction of TXNRD1 was between 3- and 4-fold with LPS, Pam3 or FSL-1. 
The effect was much stronger on HMOX1, with Pam3 and FSL-1 inducing it about 
15-fold and LPS 30-fold.  
Therefore, like in mouse RAW 264.7 cells, LPS induced the expression of all genes. 
The main difference between human THP-1 cells and mouse RAW 264.7 cells was 
that in THP-1 cells Pam3 or FSL-1 were also effective in inducing all three genes; 
this is not surprising given the high sensitivity of THP-1 cells to stimulation with 
TLR1/2 and TLR2/6 agonists [25, 26].  
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Both CLO75 and R-848 induced low levels of HMOX1 (HMOX1 mRNA, fold change 
vs control, mean ± SD, N=4;  CLO75: 3.5 ± 0.1; R-848: 3.1 ± 0.3), significantly 
different from control levels when analysed by Student’s t-test (both P<0.001 vs 
control); however, significance was lost after correction for multiple comparisons 
(Figure 2). Exactly the same picture was obtained in terms of TNF levels (not 
shown). Of note, R-848 concentration was increased from 1 µg/ml in RAW 264.7 
cells to 10 µg/ml in THP-1 to achieve at least some TNF production (about 100 
pg/ml, not shown); CLO75 concentration was maintained at 10 µg/ml as in RAW 
cells since already high, after verifying that it induced some TNF production also in 
THP-1 cells (about 30 pg/ml, not shown).  Low expression of TLR7 and TLR8 in 
THP-1 cells, and low sensitivity to stimulation with TLR7/8 agonists, have been 
previously reported [25, 27].  
In addition, poly IC (TLR3) which induced HMOX1 expression in RAW 264.7 cells 
(Figure 1), did not have any effect in THP-1 cells (Figure 2), maybe due to the low 
TLR3 expression in THP-1 cells [27]. As in RAW 264.7 cells, stimulation with the 
TLR9 agonist ODN2216 was ineffective (Figures 1 and 2). 
Since LPS was a good inducer of all genes both in human THP-1 cells and in mouse 
RAW 264.7 cells, we investigated the mechanisms mediating LPS induction of the 
three genes using the RAW 264.7 cells as a model. 
To confirm whether LPS induction was mediated by TLR4, we used neoseptin, a 
synthetic TLR4 agonist [17]. As shown in Figure 3, neoseptin induced expression of 
each of the investigated genes in RAW 264.7 cells to an equal or greater extent than 
LPS. 
 
3.2 Involvement of ROS and protein kinases 
To investigate the role of ROS we used an antioxidant (NAC) or a TLR-independent 
inducer of ROS (PMA) [28]. PMA induced all three genes, to a similar extent as LPS 
(Figure 4 A-C). It should be noted that, with both stimulants, the extent of induction of 
HMOX1 was greater, in all experiments, than that of PRDX1 or TXNRD1. PRDX1 
and TXNRD1 gene expression was unaffected by NAC treatment (Figure 4A, B) 
suggesting that, in our experimental model, the increased expression of these genes 
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is not mediated via LPS- or PMA-induced ROS. However, HMOX1 gene expression 
decreased with NAC treatment, suggesting that ROS are involved in the regulation of 
HMOX1 by LPS and PMA (Figure 4C). 
Because both PMA and LPS activate PKC, and this mediates ROS production in 
activated RAW264.7 cells [29], we tested the effect of staurosporine, a pan-specific 
protein kinase inhibitor. Staurosporine, added for 30mins prior to the addition of PMA, 
decreased induction of all genes (Figure 4D-F), suggesting that PKC is involved in 
PMA-induced gene expression. However, it decreased LPS-induced HMOX1 
expression (Figure 4F) but not PRDX1 or TXNRD1 (Figure 4D, E), indicating the 
existence of differential mechanisms for LPS induction of the three genes.  
  
Discussion 
Our results indicate that, although PRDX1, TXNRD1, and HMOX1 are all Nrf2 target 
genes, each of them had unique expression profiles in response to activation of 
different TLRs. The pattern of induction of PRDX1, TXNRD1 and HMOX1 by TLRs 
differs between THP-1 and RAW 264.7 cells. While induction of all three genes by 
TLR4 is validated across both models, Pam3 (TLR1/2) and FSL-1 (TLR2/6) induce 
all genes in THP-1 cells whereas in RAW 264.7 cells only induction of HMOX1 by 
Pam3 is observed. In addition, CL075 and R-848 (both TLR7/8) are effective only in 
the mouse system; this is probably reflecting a more general lower responsiveness 
of THP-1 cells to TLR7/8 stimulation [25]. In both the human and mouse cell lines 
tested, HMOX1 was the gene which was induced the most, the extent of induction 
being HMOX1>TXNRD1>PRDX1. 
Nrf2-mediated induction of HMOX1 has been previously reported in RAW 264.7 cells 
following stimulation of TLR2/6, TLR4, TLR7 and TLR9 [30]. It should be noted, 
however, that although HMOX1 is considered a prototypic Nrf2 target gene, it can 
also be induced by LPS via Nrf2-independent pathways as a partial induction of 
HMOX1 by LPS is also observed in the presence of Nrf2 siRNA [31]. Others have 
shown that, in vivo, LPS is a more potent inducer, in terms of fold induction in the 
liver, of HMOX1 than PRDX1, while both genes are induced to the same extent by 
the electrophile butylated hydroxyanisole [32], suggesting an additional mechanism 
to that mediated by Nrf2. Altogether, these observations all point to a higher 
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inducibility of HMOX1, and could help explain the higher level of induction we 
observed with HMOX1 compared to PRDX1 and TXNRD1. 
Additionally, although Nrf2 is a transcription factor common to all three target genes, 
and we often view them only as Nrf2 targets, other transcription factor binding sites 
can be predicted for each gene. We analyzed the predicted regulatory motifs in the 
three mouse genes using oPOSSUM version 3.0 [33]; several transcription factors 
binding sites were identified, of which Nrf2 was the only one in common to all three 
genes, as shown in Table 1. 
 
Table 1. Transcription factor binding sites for HMOX1, PRDX1 and TXNRD1 
Gene Transcription factors 
HMOX1 
Sox2, HNF1A, Pou5f1, MYC::MAX, HNF1B, NHLH1, NFE2L2, Arnt, 
Nr2e3, TAL1::TCF3, MAX, Mycn, Myc, USF1 
PRDX1 
NFE2L2, PPARG::RXRA, HNF4A, TBP, EBF1, SP1, SOX9, FOXI1, 
CEBPA, Klf4, MZF1_5-13, Hand1::Tcfe2a, Sox5, NKX3-1, Nobox, 
Gfi, Arnt::Ahr, FOXA1, RUNX1, NR4A2, Sox17 
TXNRD1 
Sox2, Pou5f1, TEAD1, HLF, Egr1, NFE2L2, IRF1, STAT1, MEF2A, 
NFIL3, Nr2e3, RELA, INSM1, TAL1::TCF3, NF-kappaB, MAX, Foxq1, 
Zfx, RORA_1, CREB1 
Transcription factor binding sites with a Fisher score > mean+1*SD, predicted using 
oPOSSUM version 3.0 [33]. Nrf2 is termed NFE2L2 in the table. 
 
This, along with our findings on the differential regulations of these genes by different 
TLRs, indicates that considering PRDX1, HMOX1 and TXNRD1 purely as Nrf2 
targets is an oversimplification. Further work will be required to identify the 
differential role of the transcription factors involved in the induction of these genes by 
LPS and other inflammatory agents.  
Our finding that the expression of the three genes can be induced with PMA 
suggests a role for PKC, as confirmed by inhibition of PMA-induced expression of all 
genes by staurosporine. This does not exclude an involvement of Nrf2, which can be 
activated through PKC-induced phosphorylation [34]; of note, staurosporine inhibits 
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PMA-induced transcription of Nrf2-target genes [35].  PKC can be activated by LPS 
[36], but staurosporine inhibits only LPS-induced HMOX1 and not PRDX1 and 
TXNRD1; this suggests that PKC might mediate only LPS induction of HMOX1, 
affecting a pathway partly independent of Nrf2, since it only induces HMOX1. 
However, it should be mentioned that, although staurosporine is widely used as a 
PKC inhibitor, it can also inhibit other protein kinases [37]. 
The potential role of ROS is another issue that needs to be clarified. Previous 
studies have shown that LPS can induce Nrf2 activation independently of ROS [31], 
possibly through the GTP-binding protein RAC1  [38]. Our experiments using the 
antioxidant NAC showed that NAC had no effect on LPS- or PMA-induced PRDX1 
nor on TXNRD1 expression, but did reduce HMOX1 expression suggesting that this 
is a more redox-sensitive gene (Figure 4). It is known that PRDX1, TXNRD1 and 
HMOX1 are induced by oxidative stress, but the results presented here suggest that 
some genes may be more susceptible to changes in redox state than others [39]. A 
study with HOCl has shown that HMOX1 is induced at lower HOCl concentrations, 
with the extent of induction similar to the one we observed: 
HMOX1>TXNRD1>PRDX1 (Supplementary file 2 in [40]). 
Elucidating the regulation of PDORs in inflammation may be important in exploring 
new avenues for the therapy of inflammatory disease. In this respect, it is important to 
remember that an inhibitor of TXNRD, auranofin, is used in the therapy of rheumatoid 
arthritis [41] while the Nrf2 activator dimethyl fumarate is used in the treatment of 
multiple sclerosis [42, 43]. The identification of pathways that fine-tune TLR responses 
may be important in the development of anti-inflammatory agents that have a lesser 
impact on the innate immunity against pathogens.    
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Figure 1. Nrf2 target gene expression induced by agonists of different TLRs in 
mouse RAW 264.7 cells. TaqMan qPCR analysis of PRDX1 (A), TXNRD1 (B) and 
HMOX1 (C) gene expression in RAW 264.7 cells stimulated with TLR agonists as 
described in Methods. Data were normalised to HPRT1 and expressed as fold change 
vs one control sample (n≥8, mean±SD). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05  
vs control by one-way ANOVA followed by Dunnett’s multiple comparisons test.   
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Figure 2. Nrf2 target gene expression induced by agonists of different TLRs in 
human THP-1 cells.TaqMan qPCR analysis of PRDX1 (A), TXNRD1 (B) and 
HMOX1 (C) gene expression in THP-1 cells stimulated with TLR agonists as 
described in Methods. Data were normalized to HPRT1 and expressed as fold 
change vs one control sample (n=4, mean±SD). ****P<0.0001 vs control by one-way 
ANOVA followed by Dunnett’s multiple comparisons test.  
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Figure 3. PRDX1, TXNRD1 and HMOX1 gene expression is increased with the 
TLR4 agonist neoseptin. TaqMan qPCR analysis of PRDX1 (A), TXNRD1 (B) and 
HMOX1 (C) gene expression in RAW 264.7 cells stimulated for 6h with LPS (10ng/ml) 
or neoseptin (25μM). Gene expression values were normalised to HPRT1 and 
expressed as fold change vs one control sample (n=12, mean±SD). ****P<0.0001, 
***P<0.001 vs control by one-way ANOVA followed by Dunnett’s multiple comparisons 
test.  
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Figure 4. Effect of NAC and the PKC inhibitor staurosporine on LPS- and PMA-
induced PRDX1, TXNRD1 and HMOX1 gene expression. TaqMan qPCR analysis 
of PRDX1 (A,D), TXNRD1 (B,E) and HMOX1 (C,F) gene expression in RAW 264.7 
cells stimulated for 6h with LPS (10ng/ml) or PMA (500ng/ml) with or without 10mM 
NAC (A,B,C) or 100 mM staurosporine (D,E,F). White bars, control; black, NAC; 
hatched, staurosporine. Gene expression values were normalised to HPRT1 and 
expressed as fold change vs one control sample (n=12, mean±SD). #P<0.05 vs 
untreated cells; ***P<0.001, *P<0.05 vs control by two-way ANOVA and Tukey’s test 
for multiple comparisons. 
